Clinical observation on the prevention of Doxorubicin-associated cardiotoxicity by astragalus injection
- VernacularTitle:黄芪注射液预防多柔比星相关性心脏毒性反应的临床观察
- Author:
Guohua ZHOU
;
Dong CAO
;
Haiyi GUO
- Publication Type:Journal Article
- Keywords:
Astragalus;
doxorubicin;
cardiotoxicity
- From:China Oncology
2001;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To evaluate the protection of astragalus injection for Doxorubicin (adriamycin)-associated cardiotoxicity. Methods:58 patients were randomized into two groups for this clinical trial. 30 patients were in the test group ,and 28 in control group. Patients in the test group received astragalus injection in 5% glucose solution once every day for two weeks starting three days before adriamycin-based chemotherapy. 28 patients in the control group began to receive oral vitamin E 100 mg twice a day and coenzyme Q10 20 mg three times a day for two weeks. Chemotherapy is the same as that in the test group. Electrocardiogram (ECG) and echocardiogram were employed to evaluate the cardiac function. Results:There was a substantial difference in ejection fracton between the two groups,but the difference was not statistically significant. Statistically significant differences were observed in the two groups with regard to all other parameters,including abnormal changes in ECG and LVIDD、LVISD、A/E、FS. Conclusions:Astragalus injection is a good drug which can prevent the occurrence of acute cardiotoxicity associated with adriamycin. It can also reduce the occurrence of chronic cardiotoxicity.
